CELC Celcuity Inc.
CELC Celcuity Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-08-17 1 neutral converging
POC $91.06 · VWAP $92.81 · -0.4% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 watchlist
CELC Price Structure
Loading timeframes…
Peers
Every watchlist CELC belongs to, members best 30-day change first — CELC highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported the quarter ending 2026-03-31: diluted EPS $-0.97, net income $-53M (SEC filing). Across the print the stock moved +8.1% (close before → first close after).
full note →Against street estimates
How CELC's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about CELC from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 42 days ago · Jul 7
- CELC News Today | Why did Celcuity stock go down today?
- Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026
- Celcuity Inc. (CELC) Q1 2026 Earnings Call Transcript
- Q4 2025 Celcuity Inc Earnings Call Transcript
- Celcuity Inc. (CELC) Q3 2025 Earnings Call Transcript
CELC research tape
16 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.